论文部分内容阅读
目的:评价口服普萘洛尔治疗婴幼儿眶周血管瘤的临床疗效与安全性。方法 :2012年5月—2014年1月,30例婴幼儿眶周血管瘤患儿接受并完成口服普萘洛尔治疗。其中男10例,女20例;年龄2~13个月,平均4.8个月。服药剂量1.0~1.5 mg/kg,每天1次顿服。治疗时间4~38周,平均疗程19周。第1次复诊为2周,以后每个月复诊1次,定期拍照、记录血管瘤的颜色、质地、大小变化,观察并及时处理治疗期间的不良反应,按4级评分法对疗效进行评价。结果:随访3~10个月,疗效评定结果Ⅰ级(差)0例,Ⅱ级(中)2例,Ⅲ级(好)9例,Ⅳ级(优)19例。所有患儿服药30 min后均出现心率减慢,血压降低,2 h后达高峰,12 h后恢复正常,无任何临床症状。4例患儿出现轻度腹泻,1例出现睡眠改变,未见严重不良反应。结论:口服普萘洛尔治疗婴幼儿眶周血管瘤起效快,疗效显著,耐受性好,不良反应轻微,可作为首选治疗方法。
Objective: To evaluate the clinical efficacy and safety of oral propranolol in the treatment of infantile periorbital hemangiomas. Methods: From May 2012 to January 2014, 30 infants with periorbital hemangiomas underwent oral propranolol treatment. Including 10 males and 20 females; aged 2 to 13 months, an average of 4.8 months. The dose of 1.0 ~ 1.5 mg / kg, day 1 Dayton clothing. Treatment time 4 to 38 weeks, the average course of 19 weeks. The first visit was 2 weeks, followed by 1 visit every month. Regular photographs were taken to record the changes in color, texture and size of hemangiomas. The adverse reactions during the treatment were observed and evaluated timely. The curative effect was evaluated according to the 4-point scale. Results: The follow-up ranged from 3 to 10 months. There were 0 grade Ⅰ, 2 grade Ⅱ, 9 grade Ⅲ, and 19 grade Ⅳ in the curative effect. All children were slowed down after 30 min of medication, blood pressure, reached peak after 2 h, returned to normal after 12 h, without any clinical symptoms. 4 cases of mild diarrhea in children, 1 case of sleep changes, no serious adverse reactions. Conclusion: Propranolol is an effective and safe treatment for infantile periorbital hemangioma with good curative effect, good tolerability and mild side effects. It can be used as the first choice of treatment.